Current Report Filing (8-k)
03 December 2021 - 12:01AM
Edgar (US Regulatory)
0001293310
false
0001293310
2021-12-02
2021-12-02
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest
event reported): December 2, 2021
Humanigen, Inc.
(Exact name of registrant as specified
in its charter)
Delaware
(State or other Jurisdiction of
Incorporation)
|
001-35798
(Commission File No.)
|
77-0557236
(IRS Employer Identification No.)
|
533 Airport Boulevard, Suite 400
Burlingame, CA 94010
(Address of principal executive offices,
including zip code)
(650) 243-3100
(Registrant’s telephone number,
including area code)
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2):
|
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant
to Section 12(b) of the Act:
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
Common Stock
|
HGEN
|
The Nasdaq Stock Market LLC
|
Indicate by check mark whether the registrant is an
emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange
Act of 1934 (17 CFR §240.12b-2).
Emerging growth company ¨
If an emerging growth company, indicate by check mark if
the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. ¨
As previously announced, management
of Humanigen, Inc. (the “Company”) will host a conference call and webcast to discuss The Lancet Respiratory Medicine publications
and provide a corporate update at 8am EST on December 2, 2021. A copy of the presentation management will use during its conference call
and webcast is attached hereto as Exhibit 99.1 and incorporated herein by reference. In addition, this presentation will be made available
on the Company's website, www.humanigen.com.
|
Item 9.01.
|
Financial Statements and Exhibits
|
(d) Exhibits
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
Humanigen, Inc.
|
|
|
|
By:
|
/s/ Cameron Durrant
|
|
|
|
Name: Cameron Durrant
Title: Chairman of the Board and Chief Executive Officer
|
Dated: December 2, 2021
Humanigen (CE) (USOTC:HGEN)
Historical Stock Chart
From Jul 2024 to Jul 2024
Humanigen (CE) (USOTC:HGEN)
Historical Stock Chart
From Jul 2023 to Jul 2024